Mineralys Therapeutics Files 8-K
Ticker: MLYS · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1933414
Sentiment: neutral
Topics: 8-K, other-events
TL;DR
Mineralys Therapeutics filed an 8-K, something happened, details TBD.
AI Summary
Mineralys Therapeutics, Inc. filed an 8-K on September 2, 2025, to report "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Mineralys Therapeutics, Inc., requiring disclosure to investors, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events,' which suggests a material event occurred but lacks specific details, creating uncertainty for investors.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- September 2, 2025 (date) — Filing date and date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Mineralys Therapeutics, Inc. in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond listing it as the item information.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated September 2, 2025, which is also the date of the report.
What is the principal executive office address for Mineralys Therapeutics, Inc.?
The principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19807.
What is the telephone number for Mineralys Therapeutics, Inc.?
The registrant's telephone number, including area code, is (888) 378-6240.
Under which section of the Securities Exchange Act of 1934 is this 8-K filing made?
This 8-K filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-09-02 17:00:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Mark
Filing Documents
- mlys-20250902.htm (8-K) — 23KB
- 0001933414-25-000107.txt ( ) — 142KB
- mlys-20250902.xsd (EX-101.SCH) — 2KB
- mlys-20250902_lab.xml (EX-101.LAB) — 23KB
- mlys-20250902_pre.xml (EX-101.PRE) — 13KB
- mlys-20250902_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 2, 2025, Mineralys Therapeutics, Inc. (the "Company") delivered written notice to BofA Securities, Inc. ("BofA") and Evercore Group L.L.C. ("Evercore"), that it was suspending its use of and terminating the prospectus supplement, dated April 11, 2024, related to the Company's common stock, $0.0001 par value per share, issuable pursuant to the terms of the ATM Equity Offering Sales Agreement, dated March 21, 2024, by and among the Company, BofA and Evercore (the "Sales Agreement"). The Company will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission; however, the Sales Agreement remains in full force and effect. A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on March 21, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MINERALYS THERAPEUTICS, INC. Date: September 2, 2025 By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary